Introduction: Surgical resection is the treatment of choice for pancreatic ductal adenocarcinoma (PDA). However, in case of venous tumor in-volvement, carcinomas are classified as borderline resectable and their preferential therapy remains controversial. The purpose of this study is to analyze the effectiveness of the surgical approach with simultaneous venous resection regarding perioperative outcome and long-term survival. Patients and methods: All patients that underwent pancreatoduodenectomy (PD) for PDA at our institution between 02/2002 and 12/2016 were analyzed retrospectively. A matched-pair analysis between patients that underwent PD with simultaneous venous resection (PDVR) and standard PD was performed to compare perioperative parameters, survival and factors relevant to long-term survival. Results: The study included 142 patients: 71 underwent PDVR and 71 underwent standard PD. Venous tumor infiltration could histopathologically be confirmed in 21 patients (29.58%). PDVR wasn’t associated with a higher rate of postoperative complications (56.34% for both groups), severe postoperative complications (28.17% vs. 23.94%) and mortality (5.63% vs. 9.86%) compared to standard PD. Median overall survival of both groups was 17 months (95% CI 10.89 - 23.11), without statistical significance between the two groups (PD 22 months, 95% CI 16.02 - 27.99 vs. PDVR 16 months, 95% CI 9.96 - 22.04, p = 0.087). Parameters associated with overall survival were his-topathologically proven venous tumor infiltration, the lymph node status and the necessity of postoperative blood transfusions. Conclusion: PDVR is justified, because peri- and post-operative morbidity and mortality, as well as long-term survival, are comparable to standard PD. Even in case of postoperatively histopathologically confirmed venous tumor infiltration, patients benefit over palliative treatment.
Pancreatic ductal adenocarcinoma is the most common type of pancreatic cancer [
Unfortunately, less than a quarter of all patients with pancreatic head cancer are suitable candidates for primary resection [
Among the latter, there is a subgroup of patients with venous tumor involvement (superior mesenteric vein [SMV] or/and portal vein [PV]) on preoperative imaging. For these patients, the standard treatment is still in the discussion: besides surgical resection followed by chemotherapy, which is the standard care for primary resectable tumors and performed increasingly in high volume centers, palliative therapy and neoadjuvant chemotherapy are alternative therapeutic options [
At the present day as well as in the near future, there is no and not likely will be a prospective randomized evaluation of venous resection within the whipple or the pylorus preserving whipple procedure, because it is hardly possible to discriminate between a direct tumor infiltration into the vein or only an inflammatory tumor adherence to the vessel, both on preoperative imaging and on intraoperative exploration. Furthermore, inter-surgeon variation in the interpretation of the adherence has to be taken into account with regard to the reliability of the results [
The intention of this study is to compare the long-term survival of patients who underwent pancreatoduodenectomy (PD) with simultaneous venous resection (SMV or/and PV) to the one of patients with standard PD and moreover to examine if there is a difference between patients with infiltrative or only inflammatory venous tumor adherence. Additionally, we want to identify the strongest predictors for long-term survival after PD with venous resection. Furthermore, we intend to analyze the morbidity and mortality between the standard and the extended procedure.
Clinicopathological characteristics of the patients were derived from our pancreaticobiliary database at the Department of General- and Visceral-Surgery, Saarland University Medical Center, Homburg/Germany.
All patients that underwent PD in curative intend due to pancreatic head cancer between February 2002 and December 2016 were analyzed retrospectively. Patients with metastatic disease and any tumor other than ductal adenocarcinoma of the pancreatic head were excluded from the study. Furthermore, patients with incomplete data acquisition were excluded, too. Before surgery, all patients included in the study have given their written consent to collect and analyze their data anonymously.
Standard PD comprised the en bloc removal of the pancreatic head, the common bile duct, the gallbladder, the duodenum and the lymphadenectomy of the levels 1 and 2. The pylorus and the distal part of the stomach were only resected if there was a direct involvement by the tumor. The reconstruction was performed either by a pancreatogastrostomy or a side to side pancreaticojejunostomy, an end to side hepaticojejunostomy and a retrocolic or orthotopic end to side anastomosis between the post-pyloric duodenum or the stomach and the jejunum.
In case of tumor adherence or infiltration into the PV and/or SMV, a pancreatoduodenectomy with simultaneous venous resection (PDVR) was performed which means that the relevant segment of the vein had to be resected, too. Depending on the extent of tumor involvement, a wedge resection or the resection of the entire segment of the vein with primary anastomosis or interposition of a graft had to be performed.
Peri- and postoperative variables being analyzed were patient characteristics of age, gender and ASA Score; operation time, blood loss, number of intraoperative as well as postoperative transfused blood units; and postoperative complications such as pancreatic fistula (as defined by the International Study Group of Pancreatic Surgery (ISGPS) [
Preoperative information about tumor extension related to the SMV or/and PV was standardized taken from the preoperative CT scan.
In hospital mortality was defined as death before discharge from hospital. Data about patients overall survival were taken from patients’ relatives, general practitioners, oncologists or from the cancer registry.
Pathological analysis included the size of the tumor itself (T1, tumor limited to the pancreas, ≤2 cm in greatest dimension; T2, tumor limited to the pancreas, >2 cm in greatest dimension; T3, tumor extends beyond the pancreas, but without involvement of the celiac axis or the superior mesenteric artery; T4, tumor involves the celiac axis or the superior mesenteric artery), the lymph node status (N0, no regional lymph node metastases; N1, regional lymph node metastases), the number of harvested and the number of positive lymph nodes, as well as lymphvascular and perineural infiltration, and the invasion of the SMV and/or PV in case of simultaneous resection. Furthermore, the residual tumor classification (R0, no residual tumor; R1, microscopic residual tumor; R2, macroscopic residual tumor) and the tumor grading (G1, well differentiated; G2, moderately differentiated; G3, poorly differentiated) were analyzed. This tumor grading classification is consistent to the seventh edition of the American Joint Committee on Cancer staging system [
In order to assess the impact of extended PD with simultaneous venous resection on morbidity and mortality, we built a matched-pair analysis, based on the type of surgery that was performed, between patients that underwent PDVR (group 1) and those who underwent standard PD (group 2) in consideration of age, gender and ASA Score.
Data were reported as mean or median values, standard deviations and frequencies. Student T-Test was used for continuous variables if they were distributed normally and Mann-Whitney-U Test if not. Chi-square test was applied in order to compare categorical variables. For all tests, two sided p value of ≤ 0.05 was considered statistically significant. Kaplan-Meier method was used in order to estimate long-term survival and the log rank test in order to analyze the difference between the two groups. Variables that showed a strong correlation with long-term survival in the univariate analysis (p-value < 0.20) were afterwards tested in multivariate model. SPSS software, version 23 was used for statistical analysis (SPSS Inc, Chicago, Ill).
Within the 15 years study period from February 2002 to December 2016 a total of 76 patients underwent pancreatoduodenectomy with en-bloc resection of the SMV or/and PV for pancreatic head adenocarcinoma with tumor adherence or infiltration into the large veins (
33 women, (group 1) at the time of surgery was 68.48 years (range 49 - 84 years). Most of them were classified as ASA (American Society of Anesthesiologists) 2 (45 Patients, 63%); none of the patients as ASA 1 or 4.
For each of these 71 patients we found a matched patient that underwent standard PD after exclusion of a venous tumor involvement at the same period (group 2). There were no statistically significant differences between the two groups in terms of gender, age and ASA-Score (
None of the patients, neither in group 1 nor in group 2, had received a neoadjuvant therapy.
On final histopathological examination the majority of tumors were classified as pT3: 64 tumors (90.14%) in group 1 and 56 (78.87%) in group 2, p = 0.773. In 21 of the 71 specimens with simultaneous venous resection due to macroscopic suspected venous tumor involvement the infiltration could histopathologically be confirmed (29.58% venous tumor infiltration).
The number of patients with positive lymph nodes (pN1 status) was higher in group 1 (n = 52, 73.24%) than in group 2 (n = 44, 61.97%), but without statistic significance (p = 0.154). In the subgroup of patients with histopathologically proven venous tumor infiltration, all but four patients (80.95%) had a pN1 status. Both the number of harvested lymph nodes and the number of positive lymph nodes per patient were significantly higher in the PDVR group than in the PD group (20.47 ± 9.99 vs. 16.42 ± 8.41 harvested lymph nodes, p = 0.025; and 3.35 ± 4.13 vs.1.73 ± 1.94 positive lymph nodes, p = 0.011). Among the patients with PDVR there was no statistically significant difference regarding the number of harvested or positive lymph nodes between those with histopathologically proven venous tumor infiltration and those without.
Furthermore, statistical analysis revealed no significant differences between the two groups regarding the lymph vascular, perineural invasion or tumor grading.
Group 1 (PDVR) n = 71 | Group 2 (PD) n = 71 | p-value | |
---|---|---|---|
Age, years (range) | 68.50 (49 - 84) | 68.00 (24 - 83) | 0.975 |
Gender | |||
male (%) | 38 (53.52) | 38 (53.52) | 1 |
female (%) | 33 (46.48) | 33 (46.48) | |
ASA-Score | |||
2 (%) | 45 (63.38) | 45 (63.38) | 1 |
3 (%) | 26 (36.62) | 26 (36.62) |
ASA-Score = American Society of Anesthesiologists-Score.
The rate of R0 resections was significantly higher in group 2 than in group 1 (71.83% vs. 53.52%, p = 0.024). Patients with histopathologically proven venous tumor infiltration had a higher incidence of R1 resections (61.90% vs. 38.10%, p = 0.156).
Between group 1 and 2 statistical analysis revealed no significant differences with respect to median operative time (PDVR 249 min [range 117 - 473 min], PD 252 min [range 122 - 515 min]) and median estimated blood loss (PDVR 400 ml [range 100 - 3000 ml], PD 400 ml [range 50 - 2000 ml]). Nevertheless, the number of patients that had received perioperative (17 [24.60%] vs. 6 [8.50%], p = 0.010) and postoperative blood transfusions (28 patients [39.40%] vs. 17 patients [23.90%], p = 0.047) was significantly higher in the PDVR group. During the operation, patients with PDVR received 0.87 ± 2.46 blood units and those who underwent PD 0.23 ± 0.85 blood units on average, p = 0.013. The number of blood units that were transfused in the postoperative course did not differ significantly between the two groups.
The extent of the operation, PDVR vs. PD, did neither influence significantly the median length of stay on the intensive care unit (2 days [range 1 - 30 days] vs. 1 day [0 - 34 days]) nor the length of hospital stay (19 days [range 8 - 93 days] vs. 17 days [8 - 87 days]).
In the postoperative course the overall complication rate was 56.34%, being equal for both groups. The incidence of major complications Clavien-Dindo ≥ 3 (PDVR 28.17% vs. PD 23.94%) as well as the rate of surgery associated complications (PDVR 42.25% vs. PD 45.07%) did not differ significantly between the two groups. Altogether 11 patients (7.75%) died within the hospital stay, 4 patients after PDVR (5.63%) and 7 patients after PD (9.86%), p = 0.346. Furthermore, there were no statistically significant differences between the PVDR and the PD group with regard to relevant postoperative pancreatic fistula, type B and C according to the definition of the ISGPF [
The median overall survival of both groups was 17 months (95% CI 10.89 - 23.11). Patients that underwent PD tend to have a longer overall survival compared to those after PDVR (22 months, 95% CI 16.02 - 27.99 vs. 16 months, 95% CI 9.96 - 22.04), but without statistical significance (
Other parameters with statistically significant influence on overall survival were a positive lymph nodes status on histopathological examination and the need for postoperative blood transfusions (
Variable | Overall (PDVR + PD) n = 142 | Group 1 (PDVR) n= 71 | Group 2 (PD) n = 71 | p-value |
---|---|---|---|---|
Median operative time, min (range) | 250 (117 - 515) | 249 (117 - 473) | 252 (122 - 515) | 0.264 |
Median estimated blood loss, ml (range) | 400 (50 - 3000) | 400 (100 - 3000) | 400 (50 - 2000) | 0.293 |
Any postoperative complications, patients (%) | 80 (56.34) | 40 (56.34) | 40 (56.34) | 1 |
Major postoperative complications, patients (%) | 37 (26.06) | 20 (28.17) | 17 (23.94) | 0.566 |
Surgery associated postoperative complications, patients (%) | 62 (43.66) | 30 (42.25) | 32 (45.07) | 0.735 |
Perioperative blood transfusion, patients (%) | 23 (16.40) | 17 (24.60) | 6 (8.50) | 0.010 |
Blood units perioperative per patient | 0.49 ± 1.72 | 0.87 ± 2.46 | 0.23 ± 0.85 | 0.013 |
Postoperative blood transfusion, patients (%) | 45 (31.70) | 28 (39.40) | 17 (23.90) | 0.047 |
Blood units postoperative per patient | 1.42 ± 3.39 | 1.49 ± 3.02 | 1.35 ± 3.75 | 0.092 |
Relevant POPF, ISGPF Grade B and C, patients (%) | 31 (21.83) | 18 (25.35) | 13 (18.31) | 0.415 |
Postoperative bleeding, patients (%) | 7 (4.93) | 3 (4.23) | 4 (5.63) | 0.698 |
DGE, patients (%) | 19 (13.38) | 6 (8.45) | 13 (18.31) | 0.084 |
Bile fistula, patients (%) | 6 (4.23) | 3 (4.23) | 3 (4.23) | 1.000 |
Reoperation, patients (%) | 19 (13.38) | 11 (15.49) | 8 (11.27) | 0.460 |
Median ICU-stay, days (range) | 2 (0 - 34) | 2 (1 - 30) | 1 (0 - 34) | 0.114 |
Median hospital-stay, days (range) | 18 (8 - 93) | 19 (8 - 93) | 17 (8 - 87) | 0.504 |
Intrahospital mortility, patients (%) | 11 (7.75) | 4 (5.63) | 7 (9.86) | 0.346 |
PD = Pancreatoduodenectomy; PDVR = Pancreatoduodenectomy with simultaneous venous resection; POPF = Postoperative pancreatic fistula; ISGPF = International Study Group of Pancreatic Fistula; DGE = Delayed gastric emptying; ICU = Intensive care unit.
Variable | Univariate analysis | Multivariate analysis | ||
---|---|---|---|---|
Median overall survival (95% CI) | p-value | Hazard ratio (95% CI) | p-value | |
Gender | ||||
Male | 22 (14.11 - 29.89) | 0.351 | ||
Female | 14 (10.37 - 17.62) | |||
ASA-Score | ||||
2 | 17 (12.39 - 21.61) | 0.668 | ||
3 | 18 (10.55 - 25.45) | |||
Type of surgery | ||||
PD | 22 (16.02 - 27.99) | 0.087 | 0.877 (0.518 - 1.483) | 0.624 |
PDVR | 16 (9.96 - 22.04) | |||
Histopathologically proven venous tumor infiltration | ||||
yes | 12 (10.97 - 13.04) | 0.048 | 1.205 (0.586 - 2.480) | 0.612 |
no | 19 (13.67 - 24.33) | |||
Tumor status | ||||
pT1 | 14 (0 - 49.28) | 0.338 |
pT2 | 34 (23.20 - 44.80) | |||
---|---|---|---|---|
pT3 | 17 (13.61 - 20.39) | |||
pT4 | 18 (9.20 - 26.80) | |||
Lymph node status | ||||
pN0 | 23.50 (14.06 - 32.94) | 0.025 | 1.133 (0.392 - 3.278) | 0.818 |
pN1 | 16 (11.89 - 20.11) | |||
Resection status | ||||
R0 | 22 (14.27 - 29.73) | 0.066 | 0.735 (0.443 - 1.220) | 0.233 |
R1 | 14 (10.12 - 17.88) | |||
Number of positive lymph nodes | ||||
0 | 24 (17.78 - 30.22) | 0.070 | 1.199 (0.674 - 2.132) | 0.537 |
1 - 2 (median) | 26 (13.12 - 38.88) | |||
>2 (median) | 14 (7.97 - 20.03) | |||
Lymph vascular invasion | ||||
L0 | 26 (20.26 - 31.74) | 0.635 | ||
L1 | 17 (12.40 - 21.60) | |||
Grading | ||||
G1 | 3 ( - ) | |||
G2 | 22 (16.42 - 27.59) | 0.062 | 1.348 (0.826 - 2.201) | 0.232 |
G3 | 14 (8.40 - 19.60) | |||
Operative time | ||||
≤250 min (median) | 17 (12.42 - 21.58) | 0.630 | ||
>250 min | 18 (8.18 - 27.83) | |||
Perioperative blood transfusion | ||||
yes | 14 (3.20 - 24.68) | 0.544 | ||
no | 17 (10.90 - 23.10) | |||
Intraoperative blood loss | ||||
≤400 ml (median) | 18 (11.00.25.00) | 0.665 | ||
>400 ml | 17 (12.00 - 22.00) | |||
Postoperative blood transfusion | ||||
yes | 12 (6.51 - 17.49) | 0.001 | 1.443 (0.848 - 2.455) | 0.176 |
no | 20 (13.98 - 26.02) | |||
Any postoperative complication | ||||
yes | 14 (9.06 - 18.94) | 0.186 | 1.598 (0.984 - 2.596) | 0.058 |
no | 18 (12.24 - 23.76) | |||
Major postoperative complication, Clavien-Dindo ≥ 3 | ||||
yes | 12 (11.36 - 12.64) | 0.233 |
no | 20 (14.48 - 25.52) | |||
---|---|---|---|---|
POPF | ||||
no, ISGPF Grade A | 18 (13.19 - 22.81) | 0.706 | ||
ISGPF Grade B,C | 13 (2.36 - 23.65) | |||
Reoperation | ||||
yes | 12 (2.50 - 21.50) | 0.974 | ||
no | 18 (10.94 - 25.06) | |||
DGE | ||||
yes | 24 (15.53 - 32.47) | 0.752 | ||
no | 17 (13.45 - 20.55) | |||
Postoperative bleeding | ||||
yes | 12 (0 - 36.01) | 0.560 | ||
no | 17 (11.03 - 22.97) |
PD= Pancreatoduodenectomy; PDVR= Pancreatoduodenectomy with simultaneous venous resection; ASA-Score = American Society of Anesthesiologists-Score; POPF = Postoperative pancreatic fistula; ISGPF = International Study Group of Pancreatic Fistula; DGE = Delayed gastric emptying.
Multivariate analysis did not reveal any parameters with significant influence on overall survival (
Pancreatic ductal adenocarcinoma rates among the most common cancer related causes of death [
Nevertheless, in time of neoadjuvant therapeutic regimes the indication for primary resection of locally advanced pancreatic head cancer or at least tumors with either tumorous or inflammatory invasion of surrounding structures remain controversial. Therefore, the objective of the present study is to compare the long-term survival as well as the peri- and postoperative morbidity and mortality after primary resection without a neoadjuvant therapy of ductal pancreatic head cancer with involvement of the PV or/and the SMV with the standard procedure.
The authors’ analysis includes 71 patients that underwent PD with simultaneous venous resection at the time of (pp-) whipple procedure and another 71 patients with the same risk factors regarding age, gender and comorbidities that underwent standard PD.
As might be reasonably expected, most of the tumors were classified pT3 at final histopathological analysis and there was no statistically significant difference in their incidence between the two groups. In approximately one third of the specimen after PDVR, the tumor infiltration into the venous wall could histopathologically be confirmed. This finding underlines the difficulty to discriminate between real tumor infiltration or only peritumoral inflammatory involvement of the vessels, both on preoperative imaging and on the basis of the intraoperative macroscopic aspect [
The authors’ analysis shows a significantly lower rate of R0 resections in the PDVR group (53.52 vs. 71.83 %, p = 0.024). Further investigation of the PDVR subgroup reveals that especially histopathologically proven venous tumor infiltration is associated with a higher incidence of R1 resection status (47.62%). This finding may be one of the reasons for the reduced overall survival of these patients [
Regarding the peri- and postoperative outcome, the present analysis shows that the PD with simultaneous venous resection is not chancier than the standard procedure and can be performed safely at high volume centers [
According to the present analysis, the median operation time and the median estimated intraoperative blood loss were comparable between the two groups. In contrast, Zhou et al. report that PDVR is associated with both a significantly higher estimated blood loss and operation time [
The median overall survival of the 142 patients included in the study was 17 months (range 1 - 144 months), which is comparable to the results of Roch et al. [
In contrast, the median overall survival of patients with histopathologically proven tumor infiltration into the venous wall was significantly worse than the survival rate of those without venous tumor infiltration [
Instead the authors are able to show that the lymph node status, N0 vs. N1, has a significant influence on overall survival. This finding can be supported by further investigations according to which the venous tumor infiltration itself is proven to be an indication for a particular aggressive tumor biology that tends to early metastatic spread [
The present study also reveals the number of positive lymph nodes as prognostic factor for long-term survival that barely missed statistical significance (p = 0.07). Similar findings are reported by Banz et al. [
Another parameter that correlates significantly with overall survival on univariate analysis is the need for postoperative blood transfusions: On the one hand, they might be an indication for postoperative complications but, in the present analysis, the rate of postoperative complications in general as well as major complications, surgical associated or specific complications like reoperations, incidence of postoperative pancreatic fistula, bile fistula, postoperative bleeding have no significant influence on overall survival. On the other hand, the negative impact of blood transfusions themselves on overall survival has been demonstrated well in the past [
There are some limitations of the study. It is a single center study and a retrospective analysis. Although it is one of the largest single center studies that have been reported, it is nevertheless a quite small group of patients and therefore the statistical power is limited. Another point is that the study does not provide information about the extent of venous resection, wedge resection or segmental resection, nor the prevalence of a postoperative chemotherapy.
With these limitations in mind, the present study demonstrates that PDVR is not associated with increased peri- and post-operative morbidity and mortality compared to standard PD and can be performed safely at high volume centers. Furthermore, the authors support the oncologic tumor resection in case of preoperative or intraoperative signs of venous tumor involvement. First, as a remarkable percentage of tumors do not infiltrate the venous wall according to the final histopathological analysis, as could be shown by the authors, it is not justified to withhold these patients the chance of cure. Second, even in case of confirmed venous tumor infiltration on postoperatively histopathological analysis, patients benefit from a better overall survival compared to patients that receive only a palliative chemotherapy [
None.
Scherber, P.R., Mikneviciute, J., Gäbelein, G., Igna, D. and Glanemann, M. (2018) Pancreatoduodenectomy with Simultaneous Venous Resection for Advanced Ductal Pancreatic Head Cancer: A Case Control Study. Surgical Science, 9, 381-398. https://doi.org/10.4236/ss.2018.911045